PPC
MCID: PRM126
MIFTS: 54

Primary Peritoneal Carcinoma (PPC) malady

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Primary Peritoneal Carcinoma

Aliases & Descriptions for Primary Peritoneal Carcinoma:

Name: Primary Peritoneal Carcinoma 56 69
Serous Surface Papillary Carcinoma 56 69
Extra-Ovarian Primary Peritoneal Carcinoma 56
Primary Peritoneal Serous Adenocarcinoma 69
Primary Peritoneal Serous Carcinoma 56
Eoppc 56
Ppc 56

Characteristics:

Orphanet epidemiological data:

56
primary peritoneal carcinoma
Age of onset: Adult; Age of death: normal life expectancy;

Classifications:



External Ids:

Orphanet 56 ORPHA168829
ICD10 via Orphanet 34 C48.2

Summaries for Primary Peritoneal Carcinoma

MalaCards based summary : Primary Peritoneal Carcinoma, also known as serous surface papillary carcinoma, is related to papillary serous adenocarcinoma and ovary papillary carcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Primary Peritoneal Carcinoma is BRCA1 (BRCA1, DNA Repair Associated), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Doxorubicin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and endothelial, and related phenotypes are Decreased viability with paclitaxel and cellular

Wikipedia : 71 Primary peritoneal cancer or carcinoma is also known as serous surface papillary carcinoma, primary... more...

Related Diseases for Primary Peritoneal Carcinoma

Diseases in the Peritoneal Benign Neoplasm family:

Primary Peritoneal Carcinoma

Diseases related to Primary Peritoneal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 160)
id Related Disease Score Top Affiliating Genes
1 papillary serous adenocarcinoma 11.3
2 ovary papillary carcinoma 11.2
3 peritonitis 10.6
4 aorto-ventricular tunnel 10.4 BRCA1 BRCA2
5 aortitis 10.3 PGR TP53
6 burn scar 10.3 BRCA1 BRCA2
7 mouth disease 10.3 ERBB2 PGR
8 mediastinum synovial sarcoma 10.3 BRCA1 BRCA2 TP53
9 lethal congenital contracture syndrome 7 10.3 BRCA1 BRCA2
10 cellular ependymoma 10.3 BRCA1 BRCA2 TP53
11 autoimmune disease of cardiovascular system 10.3 BRCA1 BRCA2 PGR
12 heart malignant hemangiopericytoma 10.3 BRCA1 BRCA2 PGR
13 mycobacterium kansasii 10.3 BRCA1 BRCA2 TP53
14 trigonocephaly, nonsyndromic 10.3 ERBB2 RET
15 glioma 10.3 ERBB2 PGR
16 childhood teratocarcinoma of the testis 10.3 BRCA1 BRCA2 RET
17 pneumonia 10.3 BRCA1 BRCA2 PGR
18 kunjin encephalitis 10.2 BRCA1 BRCA2 ERBB2
19 larynx liposarcoma 10.2 BRCA1 BRCA2 TP53
20 wolffian adnexal neoplasm 10.2 EGFR TP53
21 nemaline myopathy 8, autosomal recessive 10.2 BRCA1 BRCA2 ERBB2
22 pericardium leiomyoma 10.2 PGR TP53
23 plantar wart 10.2 CXCL8 IFNG IL10
24 parkinson disease 11 10.2 CXCL8 IFNG IL10
25 histiocytic and dendritic cell cancer 10.2 BRCA1 ERBB2 PGR
26 senile reticular retinal degeneration 10.2 CXCL8 IFNG IL10
27 pineal region mature teratoma 10.2 EGFR ERBB2
28 erb-duchenne and dejerine-klumpke palsies 10.2 CXCL8 IFNG IL10
29 central nervous system mature teratoma 10.2 ERBB2 PGR TP53
30 organ system benign neoplasm 10.2 BRCA1 ERBB2 PGR
31 male reproductive organ benign neoplasm 10.2 ERBB2 PGR TP53
32 central nervous system primitive neuroectodermal neoplasm 10.2 ERBB2 PGR TP53
33 myiasis 10.2 CXCL8 IFNG IL10
34 arthus reaction 10.2 ERBB2 PGR TP53
35 t-cell adult acute lymphocytic leukemia 10.2 ERBB2 PGR RET
36 depressed scar 10.2 CXCL8 IFNG IL10
37 burns 10.2 CXCL8 IFNG IL10
38 balkan nephropathy 10.2 CXCL8 IFNG IL10
39 anterior foramen magnum meningioma 10.2 IFNG IL10 TP53
40 vulva adenocarcinoma 10.2 ERBB2 PGR TP53
41 breast pericanalicular fibroadenoma 10.2 BRCA1 BRCA2 PGR TP53
42 villoglandular endometrial endometrioid adenocarcinoma 10.2 BRCA1 BRCA2 PGR TP53
43 paraphimosis 10.2 BRCA1 BRCA2 PGR TP53
44 classic type lipoma 10.2 CXCL8 IFNG IL10
45 fallopian tube serous adenocarcinoma 10.2 CXCL10 CXCL8 IL10
46 benign eccrine breast spiradenoma 10.2 CXCL8 IFNG IL10
47 blue toe syndrome 10.2 CXCL8 IFNG IL10
48 her2-receptor positive breast cancer 10.2 CXCL8 ERBB2 PGR
49 parasitic protozoa infectious disease 10.2 CXCL8 IFNG IL10
50 ovarian embryonal carcinoma 10.2 EGFR PGR TP53

Graphical network of the top 20 diseases related to Primary Peritoneal Carcinoma:



Diseases related to Primary Peritoneal Carcinoma

Symptoms & Phenotypes for Primary Peritoneal Carcinoma

Human phenotypes related to Primary Peritoneal Carcinoma:

56 32 (show all 6)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 56 32 Very frequent (99-80%) HP:0002017
2 constipation 56 32 Very frequent (99-80%) HP:0002019
3 abdominal pain 56 32 Very frequent (99-80%) HP:0002027
4 peritonitis 56 32 Very frequent (99-80%) HP:0002586
5 neoplasm 56 32 Very frequent (99-80%) HP:0002664
6 abdominal distention 56 32 Very frequent (99-80%) HP:0003270

GenomeRNAi Phenotypes related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR ERBB2 IL10
2 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR

MGI Mouse Phenotypes related to Primary Peritoneal Carcinoma:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.36 TP53 VEGFA BRCA1 EGFR BRCA2 CXCL10
2 embryo MP:0005380 10.31 VEGFA TP53 EGFR BRCA2 BRCA1 IFNG
3 homeostasis/metabolism MP:0005376 10.31 VEGFA TP53 CXCL10 BRCA1 BRCA2 ERBB2
4 behavior/neurological MP:0005386 10.3 VEGFA TP53 RET BRCA1 BRCA2 ERCC1
5 endocrine/exocrine gland MP:0005379 10.3 VEGFA TP53 EGFR BRCA2 BRCA1 ERBB2
6 cardiovascular system MP:0005385 10.29 TP53 VEGFA CXCL10 BRCA1 ERBB2 IFNG
7 hematopoietic system MP:0005397 10.29 TP53 VEGFA CXCL10 BRCA1 EGFR BRCA2
8 immune system MP:0005387 10.26 TP53 VEGFA CXCL10 BRCA1 BRCA2 IFNG
9 mortality/aging MP:0010768 10.26 VEGFA TP53 CXCL10 BRCA1 BRCA2 ERBB2
10 digestive/alimentary MP:0005381 10.23 VEGFA TP53 EGFR BRCA2 BRCA1 ERBB2
11 integument MP:0010771 10.21 VEGFA TP53 EGFR BRCA2 BRCA1 ERBB2
12 neoplasm MP:0002006 10.17 VEGFA TP53 EGFR BRCA2 BRCA1 IFNG
13 muscle MP:0005369 10.16 VEGFA TP53 EGFR BRCA1 ERBB2 IFNG
14 limbs/digits/tail MP:0005371 10.15 VEGFA TP53 EGFR BRCA2 BRCA1 ERBB2
15 nervous system MP:0003631 10.1 VEGFA TP53 RET CXCL10 BRCA1 BRCA2
16 normal MP:0002873 10.02 TP53 VEGFA BRCA1 EGFR BRCA2 ERBB2
17 no phenotypic analysis MP:0003012 9.91 VEGFA TP53 IFNG EGFR IL10 RET
18 reproductive system MP:0005389 9.9 VEGFA TP53 EGFR BRCA2 BRCA1 ERBB2
19 renal/urinary system MP:0005367 9.8 VEGFA TP53 BRCA1 IFNG EGFR ERCC1
20 respiratory system MP:0005388 9.56 TP53 VEGFA BRCA1 EGFR ERBB2 IFNG
21 skeleton MP:0005390 9.32 TP53 VEGFA BRCA1 EGFR BRCA2 ERBB2

Drugs & Therapeutics for Primary Peritoneal Carcinoma

Drugs for Primary Peritoneal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 293)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
4
Tamoxifen Approved Phase 3,Phase 2 10540-29-1 2733526
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
6
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
7
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
8
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
9
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
10
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
11
Capecitabine Approved, Investigational Phase 2, Phase 3, Phase 1 154361-50-9 60953
12
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
13
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
14
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
15
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
16
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
17
Trastuzumab Approved, Investigational Phase 3,Phase 1 180288-69-1 9903
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Alvimopan Approved Phase 3 156053-89-3 5488548
20
Succinylcholine Approved Phase 3,Phase 1,Phase 2 306-40-1 5314
21
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
22
Olaparib Approved Phase 3,Phase 2,Phase 1 763113-22-0 23725625
23
Epirubicin Approved Phase 3 56420-45-2 41867
24
Pancrelipase Approved Phase 3,Phase 1,Phase 2 53608-75-6
25
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
26
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
27
Pyridoxal Approved, Nutraceutical Phase 3 66-72-8 1050
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
29
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
30
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
31
Cediranib Investigational Phase 3,Phase 2,Phase 1 288383-20-0 9933475
32
Maleic acid Experimental Phase 3,Phase 2,Phase 1 110-16-7 444266
33 Alkylating Agents Phase 3,Phase 2,Phase 1
34 Mitogens Phase 3,Phase 2,Phase 1
35 Mitomycins Phase 2, Phase 3, Phase 1
36 Selective Estrogen Receptor Modulators Phase 3,Phase 2
37 Steroid Synthesis Inhibitors Phase 2, Phase 3,Phase 1
38 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
39 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
40 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
41 Hormone Antagonists Phase 3,Phase 2,Phase 1
42 Hormones Phase 3,Phase 2,Phase 1
43 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
45 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
46 Estrogen Antagonists Phase 3,Phase 2
47 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
48 Estrogen Receptor Modulators Phase 3,Phase 2
49 Estrogens Phase 3,Phase 2
50 Immunoglobulins Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 475)
id Name Status NCT ID Phase
1 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma Unknown status NCT02328716 Phase 3
2 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
3 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3
4 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
5 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3
6 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3
7 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed NCT00011986 Phase 3
8 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NCT01239732 Phase 3
9 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3
10 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3
11 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00041080 Phase 3
12 Accelerating Gastrointestinal Recovery Completed NCT01704651 Phase 3
13 A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma Completed NCT00434642 Phase 3
14 Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed NCT00075712 Phase 2, Phase 3
15 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Completed NCT00191646 Phase 3
16 S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer Completed NCT00043082 Phase 3
17 Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003636 Phase 3
18 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
19 Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer Completed NCT00769405 Phase 3
20 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
21 Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Completed NCT00443196 Phase 2, Phase 3
22 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
23 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial Completed NCT00941655 Phase 3
24 Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis Completed NCT01524094 Phase 3
25 Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis Completed NCT00052962 Phase 3
26 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3
27 Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial Recruiting NCT01506856 Phase 2, Phase 3
28 Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) Recruiting NCT02859038 Phase 3
29 Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? Recruiting NCT01611766 Phase 3
30 PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer Recruiting NCT02631876 Phase 3
31 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3
32 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02446600 Phase 3
33 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3
34 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
35 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
36 Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm Recruiting NCT01461850 Phase 3
37 Perioperative Systemic Therapy and Surgery Versus Surgery Alone for Resectable Colorectal Peritoneal Metastases. Recruiting NCT02758951 Phase 2, Phase 3
38 Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer Recruiting NCT01683864 Phase 2, Phase 3
39 D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma Recruiting NCT01882933 Phase 3
40 Trial Evaluating Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis Recruiting NCT02179489 Phase 3
41 Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis Recruiting NCT02158988 Phase 3
42 Concentration- Versus Body Surface Area-based HIPEC in Colorectal Peritoneal Carcinomatosis' Treatment Recruiting NCT03028155 Phase 3
43 Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients Recruiting NCT01226394 Phase 3
44 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3
45 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3
46 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3
47 Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer Active, not recruiting NCT01462890 Phase 3
48 A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer Active, not recruiting NCT01849874 Phase 3
49 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Active, not recruiting NCT00532194 Phase 3
50 Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer Not yet recruiting NCT03180177 Phase 3

Search NIH Clinical Center for Primary Peritoneal Carcinoma

Genetic Tests for Primary Peritoneal Carcinoma

Anatomical Context for Primary Peritoneal Carcinoma

MalaCards organs/tissues related to Primary Peritoneal Carcinoma:

39
Brain, Breast, Endothelial, Testes, Ovary, Eye, Lymph Node

Publications for Primary Peritoneal Carcinoma

Articles related to Primary Peritoneal Carcinoma:

(show top 50) (show all 124)
id Title Authors Year
1
Clinical characteristics of primary peritoneal carcinoma patients: a single-institution experience involving 8 patients. ( 28008196 )
2016
2
Letter to the Editor on "Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?" Int J Gynecol Cancer 2015;25: 1201-1207. ( 26807559 )
2016
3
Outcomes Following Interval Debulking Surgery in Primary Peritoneal Carcinoma. ( 26722051 )
2016
4
Primary peritoneal carcinoma presenting as a Sister Mary Joseph's nodule: A case report and review of the literature. ( 27354995 )
2016
5
Primary peritoneal carcinoma metastasizing to breast: a single case report and literature review from clinic to biology. ( 27807506 )
2016
6
Primary Peritoneal Carcinoma in a BRCA1/2-negative, PALB2-positive patient. ( 27547810 )
2016
7
Primary peritoneal serous papillary carcinoma presenting as a large mesenteric mass mistaken for ovarian cancer: a case of primary peritoneal carcinoma. ( 26023675 )
2015
8
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236). ( 26335594 )
2015
9
Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). ( 26089092 )
2015
10
An unusual cancer involving the rectum: two cases of localized primary peritoneal carcinoma mimicking rectal carcinoma. ( 25913798 )
2015
11
Primary Peritoneal Carcinoma Initially Presenting as Atypical Cervical Lymphadenopathy. ( 26120309 )
2015
12
Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma? ( 26035124 )
2015
13
Low-grade serous primary peritoneal carcinoma incidentally found in a hernia sac. ( 25953339 )
2015
14
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma. ( 26026738 )
2015
15
Effect of Tubal Sterilization Technique on Risk of Serous Ovarian and Primary Peritoneal Carcinoma. ( 25316178 )
2014
16
Solitary primary peritoneal carcinoma arising from the omentum. ( 25017281 )
2014
17
A case of primary peritoneal carcinoma: evidence for a precursor in the fallopian tube. ( 24403495 )
2014
18
Treatment and prognostic factors in primary peritoneal carcinoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). ( 24903764 )
2014
19
Primary peritoneal carcinoma: regional cancer institute experience. ( 25419074 )
2014
20
Cytoreductive surgery under aminolevulinic Acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: results of a phase I trial. ( 25056850 )
2014
21
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. ( 24709487 )
2014
22
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. ( 25016924 )
2014
23
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma. ( 24798935 )
2014
24
The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma. ( 23146339 )
2013
25
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study. ( 24361733 )
2013
26
Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. ( 22960352 )
2013
27
Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. ( 23791702 )
2013
28
A case of extraovarian primary peritoneal carcinoma in an oophorectomized-hysterectomized patient: a diagnostic dilemma. ( 23578412 )
2013
29
Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma. ( 23748176 )
2013
30
Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma. ( 24073344 )
2013
31
Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience. ( 23435437 )
2013
32
Prognosis of primary peritoneal carcinoma: effect of cytoreductive surgery combined with neoadjuvant chemotherapy after laparoscopic diagnosis and evaluation: a multi-center trial. ( 22439406 )
2012
33
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22155262 )
2012
34
A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. ( 22664059 )
2012
35
Extraovarian primary peritoneal carcinoma: staging with 18F-FDG PET/CT. ( 21394599 )
2012
36
Pax-8 is a reliable marker in making the diagnosis in advanced stage epithelial ovarian carcinoma and primary peritoneal carcinoma for neoadjuvant chemotherapy on cell block and biopsy specimens. ( 22348438 )
2012
37
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22366594 )
2012
38
Isolated metastatic primary peritoneal carcinoma to the breast: a rare site of disease recurrence. ( 22391350 )
2012
39
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22943879 )
2012
40
Comparison between peritoneal tuberculosis and primary peritoneal carcinoma: a 16-year, single-center experience. ( 22964319 )
2012
41
Paclitaxel plus Carboplatin Chemotherapy for Primary Peritoneal Carcinoma: A Study of 22 Cases and Comparison with Stage III-IV Ovarian Serous Carcinoma. ( 22666209 )
2012
42
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22710075 )
2012
43
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22446624 )
2012
44
Cutaneous lymphangitis carcinomatosis metastasis of extra-ovarian primary peritoneal carcinoma. ( 22949038 )
2012
45
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. ( 22772063 )
2012
46
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. ( 22037316 )
2012
47
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. ( 22047770 )
2012
48
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. ( 21277623 )
2011
49
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study. ( 21820161 )
2011
50
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. ( 21514634 )
2011

Variations for Primary Peritoneal Carcinoma

Cosmic variations for Primary Peritoneal Carcinoma:

9 (show all 17)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43989 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.596G>A p.G199E 7
2 COSM10758 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.659A>G p.Y220C 7
3 COSM44769 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.755T>C p.L252P 7
4 COSM44683 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.652G>A p.V218M 7
5 COSM10704 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.844C>T p.R282W 7
6 COSM11073 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.1024C>T p.R342* 7
7 COSM44764 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.673G>T p.V225F 7
8 COSM10794 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.796G>A p.G266R 7
9 COSM11071 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.1009C>T p.R337C 7
10 COSM44338 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.845G>A p.R282Q 7
11 COSM44603 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.835G>A p.G279R 7
12 COSM44684 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.965C>T p.P322L 7
13 COSM10988 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.772G>A p.E258K 7
14 COSM10662 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.743G>A p.R248Q 7
15 COSM43850 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.659A>C p.Y220S 7
16 COSM43737 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.830G>A p.C277Y 7
17 COSM520 KRAS peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.35G>T p.G12V 7

Expression for Primary Peritoneal Carcinoma

Search GEO for disease gene expression data for Primary Peritoneal Carcinoma.

Pathways for Primary Peritoneal Carcinoma

Pathways related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 36)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 CXCL10 CXCL8 EGFR ERBB2 FOLR3 IFNG
2
Show member pathways
13.58 CXCL10 CXCL8 EGFR ERBB2 IFNG IL10
3
Show member pathways
13.47 BRCA1 CXCL8 EGFR ERBB2 IFNG IL10
4
Show member pathways
13.2 CXCL10 CXCL8 EGFR ERBB2 IFNG IL10
5
Show member pathways
12.9 BRCA1 BRCA2 EGFR ERBB2 PGR TP53
6
Show member pathways
12.84 CXCL10 CXCL8 IFNG IL10 TP53
7
Show member pathways
12.47 EGFR ERBB2 IFNG IL10 TP53
8 12.43 BRCA1 BRCA2 ERCC1 TP53
9 12.27 BRCA1 EGFR ERBB2 MIR195 TP53 VEGFA
10 12.21 EGFR ERBB2 TP53 VEGFA
11 12.1 BRCA2 CXCL8 EGFR ERBB2 RET TP53
12 12.08 EGFR IFNG TP53 VEGFA
13 12.06 CXCL8 IL10 RET VEGFA
14 11.99 BRCA1 BRCA2 EGFR TP53 VEGFA
15 11.88 CXCL8 IL10 TP53 VEGFA
16 11.82 CXCL8 IFNG IL10
17 11.81 BRCA1 BRCA2 ERCC1
18 11.81 EGFR ERBB2 IFNG VEGFA
19
Show member pathways
11.8 EGFR ERBB2 VEGFA
20
Show member pathways
11.8 BRCA2 EGFR ERBB2 TP53 VEGFA
21 11.78 CXCL8 IFNG VEGFA
22
Show member pathways
11.74 BRCA1 BRCA2 TP53
23 11.73 CXCL8 IFNG TP53
24 11.64 BRCA1 ERBB2 ERCC1 TP53
25 11.63 EGFR IFNG IL10
26 11.63 CXCL10 CXCL8 EGFR IFNG TP53
27 11.62 BRCA1 ERBB2 TP53
28
Show member pathways
11.59 CXCL8 IFNG VEGFA
29 11.57 EGFR ERBB2 RET TP53
30 11.51 BRCA1 CXCL8 IFNG
31 11.48 EGFR IFNG TP53
32 11.45 CXCL10 CXCL8 IL10
33 11.44 CXCL8 IFNG IL10
34 11.42 EGFR RET VEGFA
35 11.38 BRCA1 CXCL8 TP53 VEGFA
36 10.88 CXCL8 EGFR ERBB2 TP53 VEGFA

GO Terms for Primary Peritoneal Carcinoma

Cellular components related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 CXCL10 CXCL8 EGFR IFNG IL10 MUC16
2 lateral element GO:0000800 8.96 BRCA1 BRCA2

Biological processes related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.89 BRCA2 EGFR ERBB2 ERCC1 TP53
2 cell surface receptor signaling pathway GO:0007166 9.88 CXCL10 EGFR ERBB2 IFNG
3 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.86 BRCA1 CXCL10 EGFR IFNG IL10 PGR
4 positive regulation of cell migration GO:0030335 9.83 CXCL10 EGFR RET VEGFA
5 positive regulation of protein phosphorylation GO:0001934 9.78 EGFR ERBB2 IFNG VEGFA
6 double-strand break repair GO:0006302 9.73 BRCA1 BRCA2 ERCC1
7 positive regulation of epithelial cell proliferation GO:0050679 9.72 EGFR ERBB2 VEGFA
8 positive regulation of MAP kinase activity GO:0043406 9.71 EGFR ERBB2 VEGFA
9 positive regulation of cell adhesion GO:0045785 9.69 ERBB2 IFNG VEGFA
10 cellular response to lipopolysaccharide GO:0071222 9.67 CXCL10 CXCL8 IFNG IL10
11 nucleotide-excision repair GO:0006289 9.63 BRCA2 ERCC1 TP53
12 negative regulation of ERBB signaling pathway GO:1901185 9.6 EGFR ERBB2
13 induction of positive chemotaxis GO:0050930 9.59 CXCL8 VEGFA
14 response to molecule of bacterial origin GO:0002237 9.58 CXCL8 IL10
15 response to gamma radiation GO:0010332 9.58 BRCA2 CXCL10 TP53
16 positive regulation of MHC class II biosynthetic process GO:0045348 9.57 IFNG IL10
17 response to X-ray GO:0010165 9.5 BRCA2 ERCC1 TP53
18 chordate embryonic development GO:0043009 9.43 BRCA1 BRCA2
19 positive regulation of gene expression GO:0010628 9.43 BRCA1 ERBB2 IFNG RET TP53 VEGFA
20 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.33 BRCA1 BRCA2 TP53
21 positive regulation of transcription, DNA-templated GO:0045893 9.17 BRCA1 BRCA2 EGFR IFNG IL10 RET

Molecular functions related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.43 EGFR ERBB2 TP53
2 damaged DNA binding GO:0003684 9.33 BRCA1 ERCC1 TP53
3 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.32 EGFR ERBB2
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR ERBB2 RET
5 cytokine activity GO:0005125 9.02 CXCL10 CXCL8 IFNG IL10 VEGFA

Sources for Primary Peritoneal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....